These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25894959)

  • 21. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].
    Saglimbene V; D'Alonzo D; Ruospo M; Vecchio M; Natale P; Gargano L; Nicolucci A; Pellegrini F; Craig JC; Triolo G; Procaccini DA; Santoro A; Di Giulio S; La Rosa S; Murgo A; Di Toro Mammarella R; Sambati M; D'Ambrosio N; Greco V; Giannoccaro G; Flammini A; Boccia E; Montalto G; Pagano S; Amarù S; Fici M; Lumaga GB; Mancini E; Veronesi M; Patregnani L; Querques M; Schiavone P; Chimienti S; Palumbo R; Di Franco D; Della Volpe M; Gori E; Salomone M; Iacono A; Moscoloni M; Treglia A; Casu D; Piras AM; Di Silva A; Mandreoli M; Lopez A; Quarello F; Catizone L; Russo G; Forcellini S; Maccarone M; Catucci G; Di Paolo B; Stingone A; D'Angelo B; Guastoni C; Pasquali S; Minoretti C; Bellasi A; Boscutti G; Martone M; David S; Schito F; Urban L; Di Iorio B; Caruso F; Mazzoni A; Musacchio R; Andreoli D; Cossu M; Li Cavoli G; Cornacchiari M; Granata A; Clementi A; Giordano R; Guastoni C; Barzaghi W; Valentini M; Hegbrant J; Tognoni G; Strippoli GF
    G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
    Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
    Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
    Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individualizing anaemia treatment: a discussion of case histories.
    Muirhead N
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi37-43. PubMed ID: 15958826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
    Wiecek A; Covic A; Locatelli F; Macdougall IC;
    Ren Fail; 2008; 30(3):267-76. PubMed ID: 18350446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
    Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
    Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC; Temple RM; Kwan JT
    Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
    Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
    J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Locatelli F; Pisoni RL; Combe C; Bommer J; Andreucci VE; Piera L; Greenwood R; Feldman HI; Port FK; Held PJ
    Nephrol Dial Transplant; 2004 Jan; 19(1):121-32. PubMed ID: 14671047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.
    Locatelli F; Aljama P; Canaud B; Covic A; De Francisco A; Macdougall IC; Wiecek A; Vanholder R;
    Nephrol Dial Transplant; 2010 Sep; 25(9):2846-50. PubMed ID: 20591813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
    Aerts JG; Swieboda-Sadlej A; Karanikiotis C; Labourey JL; Galid A; Wheeler T; Pujol B; Van Belle S
    Curr Med Res Opin; 2012 Jul; 28(7):1089-99. PubMed ID: 22642866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis.
    Khan I; Krishnan M; Kothawala A; Ashfaq A
    BMC Nephrol; 2011 May; 12():22. PubMed ID: 21595975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis.
    Wong G; Howard K; Hodson E; Irving M; Craig JC
    Nephrol Dial Transplant; 2013 Feb; 28(2):413-20. PubMed ID: 23182811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: better results for less work.
    Lines SW; Lindley EJ; Tattersall JE; Wright MJ
    Nephrol Dial Transplant; 2012 Jun; 27(6):2425-9. PubMed ID: 22207330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluctuations of haemoglobinaemia in chronic haemodialysis patients.
    De Meester J; Maes B; De Vriese A; De Moor B; Donck J; Helbert M; Bammens B; Jamar S
    Acta Clin Belg; 2011; 66(2):123-8. PubMed ID: 21630609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.
    Ludwig H; Aapro M; Bokemeyer C; Macdonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
    Eur J Cancer; 2009 Jun; 45(9):1603-15. PubMed ID: 19278851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.